Wall Street brokerages expect Redhill Biopharma Ltd. (NASDAQ:RDHL) to report earnings per share (EPS) of ($0.65) for the current quarter, according to Zacks. Three analysts have issued estimates for Redhill Biopharma’s earnings, with estimates ranging from ($0.80) to ($0.50). Redhill Biopharma reported earnings per share of ($0.70) during the same quarter last year, which suggests a positive year-over-year growth rate of 7.1%. The company is expected to announce its next earnings report on Thursday, February 22nd.

On average, analysts expect that Redhill Biopharma will report full year earnings of ($2.71) per share for the current fiscal year, with EPS estimates ranging from ($2.90) to ($2.52). For the next financial year, analysts expect that the company will post earnings of ($2.20) per share, with EPS estimates ranging from ($2.60) to ($1.80). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Redhill Biopharma.

RDHL has been the topic of a number of research analyst reports. Zacks Investment Research raised Redhill Biopharma from a “sell” rating to a “hold” rating in a report on Tuesday, August 29th. UBS AG started coverage on Redhill Biopharma in a research report on Wednesday, September 13th. They issued a “reduce” rating for the company. Roth Capital decreased their price target on Redhill Biopharma from $27.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, November 14th. Seaport Global Securities started coverage on Redhill Biopharma in a research report on Friday, October 6th. They issued a “buy” rating and a $19.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of Redhill Biopharma in a research report on Tuesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $21.10.

Redhill Biopharma (NASDAQ RDHL) traded down $0.07 during trading hours on Friday, reaching $5.02. The company had a trading volume of 52,679 shares, compared to its average volume of 93,544. Redhill Biopharma has a 1 year low of $4.82 and a 1 year high of $12.09.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp acquired a new stake in Redhill Biopharma during the 1st quarter worth about $101,000. Oppenheimer & Co. Inc. boosted its position in Redhill Biopharma by 10.8% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock worth $220,000 after acquiring an additional 2,500 shares during the period. Family Management Corp boosted its position in Redhill Biopharma by 51.5% during the 2nd quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock worth $222,000 after acquiring an additional 8,750 shares during the period. D.A. Davidson & CO. boosted its position in Redhill Biopharma by 10.0% during the 2nd quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock worth $379,000 after acquiring an additional 4,000 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Redhill Biopharma by 144.1% during the 1st quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock worth $595,000 after purchasing an additional 36,600 shares in the last quarter. Hedge funds and other institutional investors own 10.63% of the company’s stock.

WARNING: “-$0.65 Earnings Per Share Expected for Redhill Biopharma Ltd. (RDHL) This Quarter” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/0-65-earnings-per-share-expected-for-redhill-biopharma-ltd-rdhl-this-quarter/1724666.html.

About Redhill Biopharma

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Get a free copy of the Zacks research report on Redhill Biopharma (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Redhill Biopharma (NASDAQ:RDHL)

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.